Reimbursed Care Access in Malawi

Currently classified as a strictly controlled/prohibited substance under Malawi’s Pharmacy, Medicines and Poisons Act (Ninth Schedule lists psilocin and related compounds as prohibited). No authorised medical use exists outside approved clinical research in Malawi. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research in Malawi. (MDMA and related amphetamine-type psychotropics are treated as prohibited psychotropic substances under the national scheduling framework.) #

There is no public record of national regulatory registration or authorised commercial availability of esketamine (Spravato) in Malawi. Malawi’s medicines regulatory framework for registration and scheduling is administered under the Pharmacy, Medicines and Poisons legal framework and national procurement is coordinated through the Ministry of Health / Central Medical Stores Trust; searches of national schedules and procurement notices do not show an approved esketamine nasal-spray product for routine clinical use in Malawi. Esketamine (Spravato) is approved and marketed in some high-income jurisdictions under restricted programs (e.g., Janssen/SPRAVATO® approvals elsewhere) but no Malawi registration entry was identified in public national listings during review. For context on Malawi’s medicines scheduling and prohibited lists see the national Pharmacy, Medicines and Poisons schedules; for global product approvals see manufacturer regulatory announcements. # #

Ketamine is an established and commonly used anaesthetic/analgesic agent in Malawi’s health system and is included in procurement and essential-medication supply chains for hospitals (used widely at district and central hospitals), though availability can be irregular due to supply-chain and funding constraints. Clinical use is as an anaesthetic and emergency medication administered under Ministry of Health guidance; ketamine is procured for public facilities (Central Medical Stores Trust tenders and district procurement notices list ketamine injections). Availability data and operational studies of district hospitals in Malawi and the region document that ketamine anaesthesia is widely used to compensate for shortages of other anaesthetic agents. Reimbursement/access: ketamine is provided within the public hospital system where available as part of government-supplied essential medicines (i.e., not reimbursed as a separate insured psychiatric therapy product) and in private clinics/hospitals via standard fee-for-service billing; there is no specialised nationwide public reimbursement program for ketamine as a psychiatric treatment. Key sources: national medicines scheduling and procurement documents, peer-reviewed analyses of anaesthesia capacity in Malawi noting ketamine’s widespread clinical use and intermittent stock-outs. # # #

Currently classified as a strictly controlled/prohibited substance under Malawi’s Pharmacy, Medicines and Poisons Act (Ninth Schedule specifically lists N.N.-Dimethyltryptamine and related compounds as prohibited). No authorised medical use exists outside approved clinical research in Malawi. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research in Malawi. (5-MeO-DMT is encompassed by the Act’s listing of prohibited tryptamine/indole derivatives.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research in Malawi. There is no public record of authorised ibogaine clinics or programmes in Malawi. #

Currently classified as a strictly controlled substance under national drug scheduling laws (because the active tryptamine compounds and DMT derivatives are listed as prohibited), with no authorized medical use outside of approved clinical research in Malawi. Traditional plant-based sacramental use does not have legal authorisation under national drug law. #

Specifically listed in Malawi’s prohibited substances (Ninth Schedule) and therefore currently classified as strictly controlled with no authorised medical use outside approved clinical research. #

Derivatives in the 2C family (e.g., 2,5-dimethoxy-substituted phenethylamines) are explicitly referenced in Malawi’s prohibited substances lists (Ninth Schedule entries referencing 2,5-dimethoxy-4‑substituted phenethylamines), classifying 2C-X compounds as prohibited. There is no authorised medical use outside approved clinical research in Malawi. #